Efficacy and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials
Open Access
- 13 May 2020
- journal article
- research article
- Published by Springer Nature in BMC Emergency Medicine
- Vol. 20 (1) , 1-11
Abstract
Background: Acute Mountain Sickness (AMS) is a pathophysiologic process that occurs in non-acclimated susceptible individuals rapidly ascending to high-altitude. Barometric pressure falls at high altitude and it translates to a decreased partial pressure of alveolar oxygen (PAO2) and arterial oxygen (PaO2). A gradual staged ascent with sufficient acclimatization can prevent AMS but emergent circumstances requiring exposure to rapid atmospheric pressure changes – such as for climbers, disaster or rescue team procedures, and military operations – establishes a need for effective prophylactic medications. This systematic review and meta-analysis aim to analyze the incidence of AMS during emergent ascent of non-acclimatized individuals receiving inhaled budesonide compared to placebo. Methods: This current meta-analysis was conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We searched PubMed, Google Scholar and Embase for relevant studies. The efficacy of budesonide in reducing incidence of AMS was evaluated by calculating the pooled ORs and 95% CIs. The efficacy of budesonide in maintaining hemoglobin-oxygen saturation was evaluated by calculating standard mean difference (SMD) and 95% confidence intervals. Results: We found that at high altitude, inhaled budesonide was effective in reducing the incidence of mild AMS [OR: 0.37; 95% CI, 0.14 to 0.9, p = 0.042] but was ineffective in reducing the incidence of severe AMS [OR: 0.46; 95% CI, 0.14 to 1.41, p = 0.17]. Inhaled budesonide was also effective in maintaining SpO2 (SMD: 0.47; 95% CI, 0.09 to 0.84, p = 0.014) at high altitude. However, it was not effective in maintaining or improving pulmonary function at high altitude. Systematic-review found no adverse effects of budesoide in the dose used for prophylaxis of AMS. Conclusions: Our systematic review showed that prophylactic inhaled budesonide is effective in preventing mild AMS during emergency ascent but not effective in preventing severe AMS. Though statistically significant, authors recommend caution in interpretation of data and questions for further well designed randomized studies to evaluate the role of budesonide in prophylaxis of AMS during an emergent ascent.Keywords
This publication has 28 references indexed in Scilit:
- Acetazolamide for the Prevention of Acute Mountain Sickness—A Systematic Review and Meta‐analysisJournal of Travel Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude IllnessWilderness & Environmental Medicine, 2010
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009
- Emerging concepts in acute mountain sickness and high-altitude cerebral edema: from the molecular to the morphologicalCellular and Molecular Life Sciences, 2009
- Acute Mountain Sickness, High Altitude Cerebral Oedema, High Altitude Pulmonary Oedema: The Current ConceptsMedical Journal Armed Forces India, 2008
- Cerebral Edema and its ManagementMedical Journal Armed Forces India, 2003
- High-Altitude IllnessNew England Journal of Medicine, 2001
- Dexamethasone as Prophylaxis for Acute Mountain SicknessChest, 1989
- Dexamethasone in severe head injuriesNeurosurgical Review, 1979